Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Change in Accured Expenses (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Change in Accured Expenses data on record, last reported at $1.4 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 159.27% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $2.2 million, up 490.78%, while the annual FY2025 figure was $2.2 million, 490.78% up from the prior year.
  • Change in Accured Expenses reached $1.4 million in Q4 2025 per FHTX's latest filing, up from $1.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.0 million in Q3 2024 and bottomed at -$2.8 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $196850.0, with a median of $792000.0 recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: tumbled 15247.06% in 2021, then skyrocketed 764.14% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $2.4 million in 2021, then tumbled by 62.75% to $894000.0 in 2022, then crashed by 62.86% to $332000.0 in 2023, then plummeted by 829.22% to -$2.4 million in 2024, then soared by 159.27% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $1.4 million in Q4 2025, $1.2 million in Q3 2025, and $2.0 million in Q2 2025.